Market Watch
30 Oct 2026, 17:13 UTC · 2h ago
The big winners of the tech wreck are biopharma stocks
Impact · against what's priced in
The report that biopharma stocks are hitting record highs provides no new catalyst for LLY, GILD, or JNJ. This price momentum is a reflection of current valuations rather than a change in the fundamental assumptions already baked into their share prices.
- JNJ+0.00
Already priced in
- The price assumes
raised 2026 revenue guidance of $100.3–$101.3 billion
Price momentum confirms the market's acceptance of the company's current operational pace and recently raised 2026 guidance.
What JNJ's price assumes · Sep 3
Search tags
